Business Context and Reporting Period
This Form 8-K is filed by Angion Biomedica Corp. (not Elicio Therapeutics, Inc., as noted in the metadata) on May 16, 2022. The filing announces financial results for the fiscal quarter ended March 31, 2022. The company is an emerging growth company incorporated in Delaware, with its common stock (ANGN) trading on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It serves solely as a notification that the Q1 2022 results have been issued via a press release.
Guidance, Outlook, and Risks
The text does not contain specific guidance, outlook, management commentary, or risk factors. It includes a standard disclaimer stating that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for actual financial figures, as they are absent from the 8-K summary text.
- Verify the discrepancy between the metadata company name ("Elicio Therapeutics, Inc.") and the registrant name in the filing ("Angion Biomedica Corp.").
- Confirm the fiscal quarter end date of March 31, 2022, against the company's fiscal calendar.
- Check the Nasdaq Global Select Market for any trading halts or announcements related to the release of these results.